CRIS Current Research Information System

MARCHESINI REGGIANI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 22.747
AS - Asia 17.714
EU - Europa 14.992
SA - Sud America 1.135
AF - Africa 938
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 5
Totale 57.557
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.482
VN - Vietnam 4.920
SG - Singapore 4.732
CN - Cina 4.086
GB - Regno Unito 3.854
IT - Italia 3.020
DE - Germania 1.933
HK - Hong Kong 1.229
SE - Svezia 1.165
FR - Francia 1.135
UA - Ucraina 1.000
IN - India 939
BR - Brasile 841
RU - Federazione Russa 829
IE - Irlanda 542
JP - Giappone 340
ZA - Sudafrica 340
NL - Olanda 318
EE - Estonia 274
KR - Corea 264
FI - Finlandia 253
BD - Bangladesh 250
BG - Bulgaria 151
CI - Costa d'Avorio 145
CA - Canada 139
TG - Togo 130
SC - Seychelles 124
AR - Argentina 119
PH - Filippine 114
ID - Indonesia 103
TR - Turchia 92
IQ - Iraq 89
JO - Giordania 87
NG - Nigeria 83
TH - Thailandia 82
BE - Belgio 75
MX - Messico 72
CH - Svizzera 71
PK - Pakistan 65
ES - Italia 62
AT - Austria 60
PL - Polonia 56
EC - Ecuador 53
UZ - Uzbekistan 41
GR - Grecia 38
IR - Iran 37
TW - Taiwan 37
EG - Egitto 34
CL - Cile 33
MY - Malesia 32
RO - Romania 28
CZ - Repubblica Ceca 26
SA - Arabia Saudita 26
PY - Paraguay 24
AU - Australia 22
LB - Libano 21
CO - Colombia 20
PE - Perù 19
IL - Israele 17
MA - Marocco 16
LT - Lituania 15
KZ - Kazakistan 13
OM - Oman 13
KE - Kenya 12
MD - Moldavia 12
PT - Portogallo 12
SY - Repubblica araba siriana 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 11
DK - Danimarca 11
HR - Croazia 11
NP - Nepal 11
DO - Repubblica Dominicana 10
UY - Uruguay 10
AZ - Azerbaigian 9
VE - Venezuela 9
AL - Albania 7
BO - Bolivia 7
DZ - Algeria 7
HN - Honduras 7
HU - Ungheria 7
JM - Giamaica 7
PS - Palestinian Territory 7
YE - Yemen 7
ET - Etiopia 6
LK - Sri Lanka 6
SI - Slovenia 6
SK - Slovacchia (Repubblica Slovacca) 6
AO - Angola 5
MU - Mauritius 5
NO - Norvegia 5
PA - Panama 5
A2 - ???statistics.table.value.countryCode.A2??? 4
CR - Costa Rica 4
GE - Georgia 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BH - Bahrain 3
GT - Guatemala 3
Totale 57.501
Salva come PNG Salva come JPEG
Città #
Southend 3.341
Singapore 3.211
Fairfield 2.590
Ashburn 2.185
Woodbridge 1.268
San Jose 1.223
Hong Kong 1.175
Seattle 1.168
Santa Clara 1.130
Wilmington 1.107
Ho Chi Minh City 1.084
Houston 1.057
Chandler 1.052
Hanoi 975
Cambridge 913
Princeton 795
Dong Ket 678
Ann Arbor 676
Jacksonville 666
Hefei 556
Beijing 503
Dublin 495
Boardman 493
Lauterbourg 434
Bologna 358
Westminster 334
Nanjing 318
Padova 304
Los Angeles 301
Tokyo 301
Council Bluffs 289
Berlin 276
Helsinki 227
New York 210
Buffalo 205
Seoul 202
Dallas 194
Milan 190
Rome 176
Turin 170
Saint Petersburg 161
San Diego 156
Jinan 150
Shenyang 148
Sofia 148
Abidjan 145
Haiphong 141
Lomé 130
Da Nang 128
Frankfurt am Main 127
Mülheim 120
Redondo Beach 115
São Paulo 103
Hebei 97
Nanchang 96
Changsha 90
Guangzhou 87
Amman 85
Redmond 83
Tianjin 83
Abeokuta 82
Shanghai 81
Medford 80
Des Moines 76
Falls Church 74
Brussels 71
Mahé 70
Chicago 69
The Dalles 69
Verona 69
London 67
Zhengzhou 61
Johannesburg 60
Yubileyny 57
Ha Long 56
Phoenix 54
Bengaluru 53
Biên Hòa 51
Dearborn 50
Hải Dương 50
Jiaxing 50
Hangzhou 49
Norwalk 49
Munich 48
Montreal 47
Nuremberg 47
Redwood City 46
Thái Nguyên 46
Ningbo 45
Quận Bình Thạnh 43
Bremen 42
Falkenstein 42
Olalla 41
Baghdad 40
Jakarta 40
Naples 40
Florence 39
Parma 39
Can Tho 37
Paris 37
Totale 37.390
Salva come PNG Salva come JPEG
Nome #
Il diabete con epatopatia 892
Quanto mangio veramente? 560
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 548
Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. 478
Prevalenza delle disfunzioni sessuali femminili nelle donne in menopausa con sindrome metabolica. 373
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 342
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 313
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial 294
An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers 272
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease 270
Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases 268
Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. An overview 267
Does the liver accelerate ageing: Talking muscles and liver? 259
Prevalence of Sexual Dysfunction among Postmenopausal Women with and without Metabolic Syndrome. 255
NAFLD e cirrosi epatica 247
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 247
A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity 241
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 238
Acute heart failure in the emergency department: a follow-up study 236
Double-heterozygous mutations involving both HNF1A (MODY3) and HNF4A (MODY1) genes: a case report 235
The Role of Medications for the Management of Patients with NAFLD 234
A controlled, class-based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity 233
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential 230
Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus 222
Biomechanical and functional alterations in the diabetic foot: Differences between type I and type II Diabetes 222
Nonalcoholic fatty liver and insulin resistance: a cause-effect relationship? 220
A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in non-alcoholic fatty liver disease 219
Effects of cognitive-behavioral therapy on eating disorders: neurotransmitter secretory response to treatment 219
Approcci nutrizionali nella steatoepatite non alcolica 219
Management of non-alcoholic fatty liver disease 218
Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients 217
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 215
Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity 214
Non-alcoholic steatohepatitis in patients cared in metabolic units 212
A physical activity program to reinforce weight maintenance following a bheavior program in overweight/obese subjects. 211
Long-term weight loss maintenance for obesity: A multidisciplinary approach 211
Psychological status and depression in patients with liver cirrhosis 210
The metabolic syndrome in treatment-seeking obese persons 208
Emotional intelligence, emotion regulation and affectivity in adults seeking treatment for obesity. 208
Comparison of WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes 208
A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department 206
Eating habits in patients affected by metabolic syndrome and liver disease (hepatitis, cirrhosis and liver transplant) 206
Weight cycling in treatment-seeking obese persons. Data from the QUOVADIS study 203
Are behavioral approaches feasible and effective in type 2 diabetes? A propensity score analysis 203
Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease 203
Pathogenetic mechanisms and cardiovascular risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance 202
The construct validity of the Short Form-36 health survey and its relationship with BMI in obese outpatients 201
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 201
Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting 200
Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy 200
Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis (NAFLD/NASH): treatment 199
Cognitive-behavioral treatment of nonalcoholic fatty liver disease: a propensity score-adjusted observational study 198
Psychological profile and quality of life of morbid obese patients attending a cognitive behavioural program 197
A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. 196
Weight loss for a healthy liver 196
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 192
Reply to: “Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients” 191
Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program 191
Psychological distress in morbid obesity in relation to weight history 190
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? 188
A position statement on NAFLD/NASH based on the EASL 2009 special conference 186
The association between emotional intelligence and weight loss after a psychoeducational intervention for obese patients. 186
Weight loss expectations in obese patients seeking treatment at medical centers 185
Behavioral aspects of nonalcoholic fatty liver disease: diet, causes, and treatment 184
Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women 184
Which treatment for nonalcoholic fatty liver disease? 183
Effects of cognitive-behavioral treatment for weight loss in the family members 182
A psychological support program for individuals with type 1 diabetes 182
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting 182
Progetto "GULLIVER". Intervento nutrizionale via internet nella sindrome metabolica 181
Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes 180
Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. 178
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? 178
Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery 178
Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study 178
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs 177
Metabolic Syndrome and NASH 177
Obesity-associated liver disease 177
3D bone architecture in weight-bearing combined to pressure measurements in the diabetic foot 177
Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy 176
Eating behavior affects quality of life in type 2 diabetes mellitus 176
The management of severe hypoglycemia by the emergency system: The HYPOTHESIS study 175
Lifestyle changes for the treatment of nonalcoholic fatty liver disease-a 2015-19 update 175
Steatosi epatica non alcolica e obesità 174
Dual-Energy X-Ray Absorptiometry and Newest Technology: A Therapeutic Index for Different Treatment Programs in the Management of Obesity? 174
Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study 174
DXA-assessed changes in body composition in obese women following two different weight loss programs 174
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 174
Dati preliminari sullo studio della sintomatologia ortoressica tra pazienti diabetici affetti da epatopatia. 174
Prospective validation of a proposal for diagnosis and management of patients attending the emergency department for mild head injury 173
Trattamento dell’obesità: La lezione della storia 173
Massive weight loss without surgery in a super obese patient 173
A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry 172
Compulsive exercise to control shape or weight in eating disorders: Prevalence, associated features and treatment outcome 172
Continuous care in the treatment of obesity. An observational multicenter study 171
Update on nutritional supplementation with branched-chain amino acids 171
Venesection for nonalcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study 171
Vascular risk in young women with polycystic ovary and polycystic ovary syndrome 171
AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. 170
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease 169
Totale 22.215
Salva come PNG Salva come JPEG
Categoria #
all - tutte 160.978
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 160.978
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.270 0 0 0 0 0 0 0 0 0 0 0 1.270
2021/20226.150 612 229 456 457 679 371 171 470 242 263 1.150 1.050
2022/20235.985 685 818 315 736 420 394 253 330 1.010 178 531 315
2023/20242.040 133 318 117 148 159 360 136 194 82 161 129 103
2024/20257.476 321 1.148 597 583 1.578 394 465 210 114 358 186 1.522
2025/202617.988 1.873 1.653 1.581 1.395 1.858 1.064 1.755 1.180 3.001 1.167 751 710
Totale 58.343